COVID-19 was a nightmare on one level; on another, it was a bonanza for Roche Holding AG and its investors. With the pandemic in the rear-view mirror, sales of therapies for the virus have fallen markedly. This, and the appreciation of the Swiss franc against most currencies, left Roche’s first-quarter sales 6% lower than in the same period last year.
Key Takeaways
- Roche’s Q1 sales fell 6% compared with the first three months of 2023, though they rose 2% on a constant currency basis
Knowing this was coming, the group has taken steps to improve its growth – and that means culling unpromising therapies...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?